What is the clinical significance of an elevated immunoglobulin M (IgM) level?

Clinical Significance of Elevated IgM

Elevated IgM levels have distinct clinical significance depending on the context: they may indicate acute infection (when IgM antibodies appear), monoclonal gammopathies (particularly IgM MGUS or Waldenström's macroglobulinemia), primary immunodeficiency syndromes (hyper-IgM syndrome), or autoimmune/inflammatory conditions.

Acute Infection

• IgM antibodies indicate recent or acute infection, as they appear early in the immune response before IgG antibodies develop 1.
• For rubella diagnosis, the presence of IgM antibody or a significant rise in IgG levels confirms acute infection 1.
• In viral hepatitis, IgM anti-HAV positivity confirms acute hepatitis A, while IgM anti-HBc indicates acute hepatitis B 1.
• The acute-phase serum specimen should be drawn within the first 7 days after symptom onset for optimal IgM detection 1.

Monoclonal IgM Gammopathies

IgM MGUS and Waldenström's Macroglobulinemia

• IgM monoclonal gammopathy represents 15-20% of all MGUS cases and progresses to Waldenström's macroglobulinemia (WM) or light chain amyloidosis at approximately 1% per year 1, 2.
• IgM MGUS is defined by M-protein <30 g/L, bone marrow plasma cells <10%, and absence of end-organ damage 1.
• WM is characterized by hypersecretion of IgM, excess lymphoplasmacytoid cells in bone marrow, and potential visceral organ involvement 1.

Clinical Complications of Elevated IgM

• IgM levels >60 g/L are associated with imminent risk of symptomatic hyperviscosity and constitute a treatment indication 1.
• Due to its pentameric structure, IgM has high intrinsic viscosity and precipitates more readily than other immunoglobulin subtypes 2.
• Symptomatic hyperviscosity requires immediate plasmapheresis, which removes 80% of IgM protein 1.
• IgM is more commonly associated with autoimmune phenomena including cold hemagglutinin disease, cryoglobulinemia, and IgM-related neuropathies 2.

Treatment Indications for WM

Treatment should be initiated for 1:

• Symptomatic hyperviscosity
• Anemia or pancytopenia
• Bulky adenopathy or symptomatic organomegaly
• Symptomatic cryoglobulinemia or neuropathy
• Constitutional symptoms

The level of monoclonal IgM alone (below 60 g/L) is not an indication to start treatment 1.

Primary Immunodeficiency: Hyper-IgM Syndrome

• Hyper-IgM syndrome is characterized by low or absent IgG, IgA, and IgE with normal or increased IgM levels 3, 4.
• This represents a defect in immunoglobulin class switch recombination (CSR) 4.
• Clinical manifestations include recurrent infections (pulmonary and gastrointestinal), autoimmune disorders, hematologic abnormalities, lymphoproliferation, and malignancies 3.
• The majority of immunodeficient patients with recurrent sinusitis have defects in humoral immunity 1.

Autoimmune and Inflammatory Conditions

• Elevated IgM levels occur in up to 45% of primary sclerosing cholangitis (PSC) cases 1.
• Increased IgM is associated with various autoimmune diseases and chronic inflammation 5.
• In autoimmune hepatitis, increased IgA or IgM levels (rather than IgG predominance) suggest alternative diagnoses such as alcoholic steatohepatitis or primary biliary cirrhosis 1.

Prognostic Significance

• High levels of immunoglobulins, particularly IgG but also IgM, are associated with elevated risk of all-cause mortality and infectious disease mortality 6.
• In IgM MGUS, clonal burden (bone marrow plasma cell percentage and M-protein level) and biological characteristics predict progression risk 1.

Diagnostic Approach

When encountering elevated IgM, evaluate for:

1. Acute infection: Check for recent illness onset, specific IgM antibodies for suspected pathogens 1
2. Monoclonal vs. polyclonal: Perform serum protein electrophoresis (SPEP) and immunofixation 1
3. Quantitative immunoglobulins: Measure IgG, IgA, and IgM levels to identify selective elevation 1
4. If monoclonal IgM detected: Bone marrow biopsy, assess for hyperviscosity symptoms, evaluate for end-organ damage 1
5. If polyclonal with low IgG/IgA: Consider hyper-IgM syndrome, check for recurrent infections 3, 4

Critical Pitfalls

• Rituximab induces an IgM flare in 30-80% of WM patients, which may exacerbate IgM-related complications and does not reflect disease progression 1.
• Conversely, bortezomib and ibrutinib can suppress IgM levels independent of tumor cell killing 1.
• When serum IgM levels appear discordant with clinical progress, bone marrow biopsy should be performed to clarify disease burden 1.